Adline Chem Lab (524604)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Reported profit growth of 50% shows some momentum, albeit from a negligible base.
• Piotroski F-Score of 5/9 indicates moderate health on the nine-point checklist.
• The stock has more than doubled off its 52-week low of ₹7.60, signalling market interest in a potential revival.

Concerns

• P/E of 273.33 and PEG of 5.47 imply the stock is priced for perfect execution, while sales growth is 0%.
• ROE of -1.26% and ROCE of 0.00% show no return for shareholders or capital providers.
• Latest quarter sales of ₹0 Cr and net profit of ₹-0 Cr reveal a dormant or loss-making operation.
• No dividend, no promoter holding disclosure, and no book value data make fundamental analysis unreliable.

AI Analysis

Let’s examine Adline Chem Lab with Buffett and Graham’s framework. The market cap is just ₹10 crore, so even a small investor could theoretically own the whole company. But smallness is not a reason to buy. The trailing P/E of 273.33 means I am paying 273 years of current earnings for this pharmaceutical business. Where is the growth to justify that? Sales growth is exactly 0.00%, and the latest quarter shows ₹0 crore in sales and ₹-0 crore in net profit. ROE is -1.26%, so equity holders are not getting a return; ROCE is 0.00%. This is not a wealth creator. The 50% profit growth figure looks impressive on the surface, but in absolute terms the company is barely earning anything. Graham would say: start with the numbers, not the rates. A rise from almost nothing to slightly less than nothing is not a business transformation. The PEG ratio is 5.47, which tells me even the projected growth is already fully paid for at this price. The Piotroski F-Score is 5/9—passable, but not a sign of financial strength. There is no dividend, no book value disclosure, and no promoter holding data. That lack of transparency is a warning. A rational investor demands a margin of safety. Here, the price sits near the top of the 52-week range at ₹15.90 against a low of ₹7.60, despite poor underlying fundamentals. This looks like speculation dressed up in a small-cap pharma story. I would rather miss the upside than lose my capital. If this is a genuine turnaround, let it show several quarters of positive sales, positive net profit, and improving ROE before I get interested. Today, it is an avoid.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer